ALT Blue background with white text: "RNAi: Advancing WVE-007 (INHBE siRNA) across treatment settings: -Dosing ongoing in Phase 2a monotherapy clinical trial in individuals with higher BMI and comorbidities. -Initiated Phase 2a combination trial. -Remain on track to initiate post-incretin maintenance trial this quarter."

ALT Blue background with white text: "RNA Editing. -Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers/ -CTA submission for WVE-008 for PNPLA3 liver disease (RNA editing) on track for 4Q 2026."

ALT Blue background with white text: "Platform. --GSK selected a GalNAc-siRNA development candidate using Wave’s proprietary SpiNA design. Three additional hepatic and extra-hepatic collaboration programs advancing towards potential candidate selection."

ALT Blue background with white text: "Financial Highlights: -Well capitalized with cash, cash equivalents, and marketable securities of $431.0 million as of September 30, 2026. -Additional $12 million milestone from GSK to be received in 4Q 2026. -Expected cash runway into 3Q 2028. Investor conference call and webcast at 8:30 a.m. ET today'."

ALT Graphic with a blue gradient background and white text. Text reads: "Research Day. November 4. 9:30 a.m. ET. Register and learn more: IR.wavelifesciences.com."

ALT Graphic with a lab image in the background and white text. Text: "Chardan's 10th Annual Healthcare Conference. Panel: 'RNA Medicines: Next-Generation RNA Therapeutics." Tuesday, October 20. 9:45 a.m. ET."

ALT Graphic with blue gradient background, an announcement icon, and white text. Text: "Wave Life Sciences Announces FDA Feedback Supports Registrational pathway for WVE-006 (RNA Editing) in AATD."

ALT Graphic with blue gradient background, an announcement icon in the top center and white text. Text: "Wave Life Sciences Announces GSK’s Selection of siRNA Program to Transition to GSK for Further Development."

ALT Graphic with a blue and purple gradient background, a headshot of Paul Bolno and white text featuring a quote by Paul. Text: "The advancement of this development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class SpiNA design siRNA. Our SpiNA siRNA compounds demonstrate superior pharmacology, including improved potency, durability and Ago2 loading versus comparator formats.”

ALT Graphic with blue background and white text: "Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity."

ALT Graphic with headshot of Chris Wright, Chief Medical Officer. Text is a quote from Chris: "Our preclinical data support the potential for enhanced fat loss and preservation of muscle with WVE-007 as compared to incretins alone. The consequence of muscle loss is particularly important since beyond strength, skeletal muscle also plays an important role in both metabolism and weight maintenance.”

ALT Graphic with text and a headshot of Monika Vnuk. Text: "Announcing the appointment of Dr. Monika Vnuk as Chief Business Office. Quote from Monica: I am energized to join the company at such an exciting moment, as its science and pipeline programs create broad opportunity to advance value-creating transactions with the ultimate aim of expanding Wave’s positive impact on patients.”

ALT A darkened image of lab equipment with white text overlay. Text: "Cantor 2026 Global Healthcare Conference. Analyst-led fireside chat. Thursday, September 10. 9:45 a.m. ET."

ALT Graphic with a lung graphic and blue text. "Join us at the European Respiratory Society Congress 2026 September 7 | 12:30 p.m. CEST Poster Presentation RNA editing for the treatment of alpha-1 antitrypsin deficiency (AATD): interim results from RestorAATion-2 Kenneth R Chapman, MsC, MD, FRCPC, FACP, FERS, Department of Medicine, University of Toronto"

ALT People stand and look at a Wave scientific poster.

ALT Graphic with a blue gradient background and white text: "Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update." White arrow pointing right.

ALT Graphic with a blue gradient background and white text: "RNAi. -Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 in individuals with obesity and comorbidities; trial will also inform WVE-007's potential in MASH, type 2 diabetes, and other cardiometabolic diseases -Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026."

ALT Graphic with a blue gradient background and white text: "RNA Editing: -FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006; data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATD." -CTA submission for WVE-008 for PNPLA3 liver disease on track for 2H 2026."

ALT Graphic with a blue gradient background and white text: "Financial highlights. -Well capitalized with cash, cash equivalents, and marketable securities of $490.6 million as of June 30, 2026 and expected cash runway into 3Q 2028. -Investor conference call and webcast at 8:30 a.m. ET today."

ALT Graphic with white text and a blue gradient background. Text: "2Q 2026 Earnings Update. Thursday, July 30 | 8:30 a.m. ET."

ALT Graphic with a loudspeaker icon, white text, and a blue, purple, pink gradient background. Text: "Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases"

ALT Graphic with a blue and purple gradient background, white text, and photo of two men sitting in chairs in front of a wooden sign with the words "Goldman Sachs" in the top corner of the sign. Text says: "The value of our chemistry platform is how we unlock human genetics so that when those compelling, high-impact, high-value targets become accessible, you can be poised to translate those innovations.” -Paul Bolno, MD, MBA. President & CEO. Goldman Sachs 27th Annual Global Healthcare Conference.

ALT Wave Life Sciences to highlight data from INLIGHT™ trial of WVE-007 for obesity at American Diabetes Association 2026 Scientific Sessions June 5-8 | New Orleans Booth #2109

ALT Graphic with text: "Silencing Hepatokine Activin E Promotes a Healthy Body Composition and Metabolic Profile in Mice Sunday, June 7 | 12:30-1:30 p.m. CT Poster 1792-P Interim Results from INLIGHT, a Phase 1 Study of Investigational WVE-007, an INHBE GalNAc-siRNA, for the Treatment of Overweight and Obesity Monday, June 8 | 12:30-1:30 p.m. CT Poster 2566-P"

ALT One woman and four men sit in red chairs on a stage with a red background. The woman is speaking and has her hands up.

ALT Graphic with white background and navy text: "Wave Life Sciences to present data from multiple RNA editing programs for liver diseases at EASL 2026"

ALT Graphic with white background and navy text: RNA editing for the treatment of alpha-1 antitrypsin deficiency (AATD) Pavel Strnad, MD Professor of Translational Gastroenterology and Senior Physician at the University Hospital Aachen, Department of Medicine III May 29 | 10:45-11 a.m. CEST Oral Presentation. RNA editing of PNPLA3 I148M decreases hepatocyte fat content Hsiu-Chiung Yang, PhD SVP of Translational Medicine May 29 | 8:30 a.m. - 5:30 p.m. CEST Poster Session: MASLD Therapy"